With the December 2012 UK Government’s announcement of a £100m investment for the sequencing of 100k genomes of NHS patients with cancer and rare diseases, Genetics confirmed its leading position at the forefront of biotech research and industry.  What are its scientific foundations? Is it healthy business?  How can its discoveries challenge patient care?

Join OBR- Glasgow panel discussion to gain fascinating and much-needed insights into the scientific background, entrepreneurship opportunities and clinical impact of Human Genome Sequencing.

To register to join the discussion please register (free of charge) on the following website http://www.oxbridgebiotech.com/events/.

Event details are as follows:

Date:  Wednesday 27th November 2013

Location:  WILT (Western Infirmary Lecture Theatre), Western Infirmary, University Place G11 6NT, B9 on Gilmorehill Campus Map.

 Schedule:         5:00pm – 6:00pm Panel discussion

                         6:00pm – 7:00pm Wine Reception & Networking

Panel:  Chair: Prof Andrew Biankin - Director of Translational Research Centre, University of Glasgow.

            Prof Darren Monckton - Professor of Human Genetics, University of Glasgow.

            Dr Roma Armstrong - ‎Senior R&D Manager, NHS Greater Glasgow and Clyde.

            Raimo Tanzi - Director Next Generation Sequencing Business Development at Life Technologies.

First published: 19 November 2013

<< 2013 Archive